Medline (NASDAQ:MDLN) Insider Sells $3,677,000.00 in Stock

Medline (NASDAQ:MDLN) insider Douglas Golwas sold 100,000 shares of Medline stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $36.77, for a total value of $3,677,000.00. Following the completion of the sale, the insider owned 23,899 shares of the company’s stock, valued at $878,766.23. The trade was a 80.71% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Medline Price Performance

MDLN opened at $35.94 on Friday. The company has a debt-to-equity ratio of 0.65, a current ratio of 4.41 and a quick ratio of 2.51. Medline has a twelve month low of $32.81 and a twelve month high of $50.88. The stock has a market capitalization of $47.21 billion and a PE ratio of 112.31. The firm’s 50 day moving average is $40.02.

Medline (NASDAQ:MDLN) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.33 earnings per share for the quarter, beating the consensus estimate of $0.29 by $0.04. The firm had revenue of $7.35 billion for the quarter. The company’s revenue was up 10.7% compared to the same quarter last year. As a group, analysts expect that Medline will post 1.49 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have commented on the company. Sanford C. Bernstein reduced their price target on Medline from $56.00 to $54.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Barclays reduced their price target on shares of Medline from $50.00 to $45.00 and set an “overweight” rating on the stock in a report on Monday, June 1st. Weiss Ratings cut Medline from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, May 15th. Citigroup lowered their price target on shares of Medline from $60.00 to $55.00 and set a “buy” rating for the company in a report on Thursday, May 7th. Finally, Tigress Financial raised their price target on Medline from $60.00 to $62.00 and gave the stock a “buy” rating in a research report on Wednesday, May 13th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Medline has an average rating of “Moderate Buy” and an average price target of $50.54.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Carlyle Group Inc. purchased a new stake in Medline during the fourth quarter worth $9,042,728,000. H&F Corporate Investors X Ltd. acquired a new stake in Medline in the 4th quarter worth approximately $4,179,591,000. Vanguard Group Inc. purchased a new stake in shares of Medline during the fourth quarter valued at $793,278,000. Morgan Stanley purchased a new stake in Medline during the 4th quarter valued at about $636,807,000. Finally, Capital Research Global Investors purchased a new stake in Medline in the fourth quarter valued at approximately $620,937,000.

Medline Company Profile

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.